Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

It has recently become clear that airways disease associated with eosinophilic airway inflammation, but not other patterns of inflammation, is closely associated with favourable short-and long-term responses to corticosteroid therapy, irrespective of the clinical context in which it occurs. Moreover, a raised exhaled nitric oxide (FE(NO)) is a reasonable marker of eosinophilic airway inflammation, which has a number of advantages as a diagnostic and monitoring tool. In this review we outline essential background information on the use of FE(NO) in clinical practice and discuss some recent work evaluating the clinical value of this technique.

Original publication

DOI

10.1080/02770900801978557

Type

Journal article

Journal

J Asthma

Publication Date

09/2008

Volume

45

Pages

523 - 531

Keywords

Asthma, Biomarkers, Breath Tests, Eosinophilia, Exhalation, Glucocorticoids, Humans, Inflammation, Nitric Oxide, Sputum